Clinical trials in Israel

200 indexed studies · 101 currently recruiting

Latest studies

RecruitingPHASE3
Global Trial in APG2575 for Patients With CLL/SLL
This study is looking into a new treatment called lisaftoclax for people with a type of blood cancer called CLL/SLL. It compares adding lisaftoclax to an existing BTK inhibitor treatment versus just using the BTK inhibitor alone, for patients who have already been on BTK inhibitors.
CLL/SLL
Israel
RecruitingPHASE3
A Gaucher Disease Gene Therapy Trial With FLT201
This study is testing a new gene therapy called FLT201 for adults with Gaucher disease type 1. It aims to see if patients can stop their current treatment after receiving FLT201 while remaining well. This is the final stage of testing before it might become available.
Gaucher Disease Type 1
Israel
RecruitingPHASE2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This study is looking into a new drug, AZD8965, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if different doses of this drug are safe and effective, compared to a dummy drug, for people with IPF, including those already on other treatments.
Idiopathic Pulmonary Fibrosis (IPF)
Israel
Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary Disease
Israel
Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's Disease
Israel
RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral Sclerosis
Israel
RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney Disease
Israel
RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's Disease
Israel
Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's Disease
Israel
Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's Disease
Israel
RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
Carcinoma, Non-Small Cell Lung
Israel
RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn Disease
Israel
RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
Non-Muscle Invasive Bladder Neoplasms
Israel
RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
Advanced Breast Cancer
Israel
RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
Cancer
Israel
Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)
Israel
RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung Cancer
Israel
Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's Disease
Israel
Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis Suppurativa
Israel
Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid Arthritis
Israel
Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative Colitis
Israel
Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)
Israel
RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Israel
Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
Prostatic Neoplasms
Israel
Active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
This study looks at new drug combinations for advanced bladder cancer. Doctors want to see if adding different medicines to pembrolizumab and enfortumab vedotin (EV) works better and is safe. The goal is to find new, effective treatments for patients.
Metastatic Urothelial CarcinomaUrothelial Neoplasms
Israel
RecruitingPHASE1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.
Neoplasms
Israel
Recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
This study looks at how well special devices work in real-world patients with a condition called an Abdominal Aortic Aneurysm (AAA). Doctors will watch patients for up to 10 years after they get these devices to see how they're doing and if there are any problems.
AAA - Abdominal Aortic Aneurysm
Israel
RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)
Israel
Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.
HIVHIV Infections
Israel
Active not recruitingPHASE3
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
This study looks at a new long-term treatment called donidalorsen for Hereditary Angioedema (HAE). Researchers want to see if it's safe, helps reduce HAE attacks, and improves quality of life for people with this condition over time.
Hereditary Angioedema
Israel
Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
Melanoma
Israel
Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
Papillary Renal Cell Carcinoma
Israel
Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
Bradycardia
Israel
Active not recruitingPHASE1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
This study is looking into a new medicine, ABBV-101, for blood cancers called non-Hodgkin's lymphoma (NHL). It will check how safe the medicine is, how it moves through the body, and if it helps people with different types of NHL that have come back or not responded to other treatments.
Hematologic Cancer
Israel
RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
Neoplasms
Israel
RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This study is testing a new medicine, efruxifermin, for people with a serious liver condition called NASH/MASH cirrhosis. It's to see if the medicine helps improve liver health in those with scarring that hasn't yet caused severe problems.
NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis
Israel
RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer Metastatic
Israel
Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
HER2-positive Breast Cancer
Israel
RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for people with moderately to severely active Crohn's disease. It's a Phase 3 study, which means it's a big step before the medicine might become widely available, looking at how well it works and if it's safe.
Moderately to Severely Active Crohns Disease
Israel
RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory Failure
Israel
RecruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
This study is looking at a new medicine called frexalimab for adults having a kidney transplant. It compares frexalimab to a standard medicine, tacrolimus, to see if it's safe and works well to prevent the body rejecting the new kidney.
Kidney Transplant Rejection
Israel
RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
Multiple Myeloma
Israel
Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular Disorders
Israel
Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)
Israel
Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's Disease
Israel
Active not recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This study looks at the long-term effects of a medicine called Humira for adults with a bowel condition called ulcerative colitis. It aims to see how well Humira works and if it's safe over a long time when used as doctors usually prescribe it.
Ulcerative Colitis (UC)
Israel
Active not recruitingPHASE3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
This study looks at two different medicines, T-DXd and T-DM1, for certain people with HER2-positive breast cancer. It's for those who still have some cancer after their first treatments. We want to see if T-DXd works better at stopping the cancer from coming back.
HER2-Positive Primary Breast CancerResidual Invasive Breast Cancer
Israel
Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
Prostatic Neoplasms
Israel
RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's Disease
Israel
Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.
Metastatic Castration-sensitive Prostate Cancer
Israel

Latest studies

Global Trial in APG2575 for Patients With CLL/SLL

A Gaucher Disease Gene Therapy Trial With FLT201

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Pan Tumor Rollover Study

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Micra Transcatheter Pacing System Post-Approval Registry

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Product Surveillance Registry

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)